NovoCure Ltd (NVCR)

NovoCure is an oncology company that has commercialised Tumor Treating Fields, a novel form of cancer therapy that uses low-intensity electric fields delivered via wearable transducer arrays to disrupt the division of cancer cells. The company’s proprietary system, Optune, was first approved by the FDA in 2011 for glioblastoma — a brain cancer with poor prognosis — and has since expanded to pancreatic cancer, non-small cell lung cancer, and mesothelioma. Unlike chemotherapy, which poisons dividing cells across the body, or radiation, which burns tissue at a point, Tumor Treating Fields operate on a different principle: the electric fields appear to interfere with the structural dynamics of cancer cells undergoing mitosis, causing them to fail to divide. The therapy is delivered through a patient’s clothing via transducer pads, making it non-invasive and tolerable for extended use.

Glioblastoma: the foundation and the proof of concept.

Glioblastoma is one of the most aggressive brain tumours, with a median survival of around 14 months even with the standard treatment of surgery, radiation, and chemotherapy. When NovoCure first received FDA approval for Optune as an adjunct to chemotherapy in newly diagnosed glioblastoma patients in 2011, the bar for efficacy was low: if Optune improved survival by a few months and was tolerable, it would be considered successful.

Early clinical data showed that Optune could improve median survival in certain patient populations. The mechanism — disrupting cancer-cell division through electric fields — is unconventional enough that it required rigorous Phase 3 trials to prove clinical benefit. Over time, glioblastoma has become the company’s most established indication, though it remains a small market in absolute terms because glioblastoma is rare and the patient population is limited.

The importance of glioblastoma is that it validated the underlying technology. Once the FDA and the medical community accepted that Tumor Treating Fields could work, the door opened to testing in other cancers.

Pancreatic cancer: the breakthrough and the growth driver.

Pancreatic ductal adenocarcinoma is one of the most lethal human cancers, with a five-year survival rate below 10% and a median survival of around one year even with chemotherapy. The PANOVA-3 Phase 3 trial tested Optune combined with gemcitabine and nab-paclitaxel (the standard chemotherapy regimen) in locally advanced pancreatic cancer. In 2023, NovoCure announced that PANOVA-3 met its primary endpoint of overall survival benefit. This was a watershed moment: the FDA granted accelerated approval for Optune Pax (the combination therapy) in locally advanced pancreatic cancer in 2024, the first new treatment approved for this indication in nearly 30 years.

Pancreatic cancer is a much larger market than glioblastoma — tens of thousands of patients annually in the United States alone. If Optune Pax gains adoption and market share, it could become a material revenue driver. The company has also initiated PANOVA-4, a Phase 2 trial testing Optune with immunotherapy in metastatic pancreatic cancer, aiming to expand into an even larger patient population.

Lung cancer: broadening the platform.

Non-small cell lung cancer is the most common type of lung cancer and represents one of the largest addressable oncology markets globally. NovoCure has a Phase 3 trial, METIS, testing Optune in combination with standard chemotherapy for brain metastases arising from non-small cell lung cancer — cancer that has spread to the brain. Results from METIS are expected in 2025, and if positive, they would open another indication and patient population.

The logic is compelling: cancer that spreads to the brain is particularly lethal and resistant to treatment. If Optune can improve survival in this population, it would address a genuine unmet need and establish NovoCure as a player in the broader lung-cancer space.

Mesothelioma and future indications.

Mesothelioma is a rare cancer arising from asbestos exposure. NovoCure has regulatory approvals in some regions for Optune in mesothelioma, though the market is much smaller than lung or pancreatic cancer. The company is also exploring Optune in other solid tumors, though at present, the approved and near-term pipeline is focused on the four indications above.

The business model: devices, treatment costs, and reimbursement.

NovoCure’s revenue comes from two sources: the upfront sale of the Optune device and the ongoing monthly treatment fees. When a patient is prescribed Optune, NovoCure provides the device, which the patient wears for several hours daily over a treatment course that typically lasts several months to a year or more. The company bills insurance companies for the monthly rental and service, creating recurring revenue throughout the patient’s therapy.

This recurring model is an important feature. Unlike a drug that is purchased once per dose or a surgical device that is implanted once, Optune generates ongoing cash flow from each patient. A successful pancreatic cancer program that treats thousands of patients annually would create a steady, predictable revenue stream.

Reimbursement is a critical risk. Insurance companies must agree to pay for Optune, and they base coverage decisions on clinical evidence of benefit, cost-effectiveness, and comparison to alternative treatments. For glioblastoma, reimbursement is established. For pancreatic cancer, with only recent FDA approval, insurance coverage is still being negotiated. A negative reimbursement determination in a major market could materially impact adoption and revenue.

Clinical and competitive risks during different phases of the cycle.

During economic expansions when healthcare spending is high and insurance companies are less cost-conscious, Optune adoption can accelerate. Oncology practices have budget room to trial new therapies, and patients have less financial pressure to refuse treatment. Conversely, during recessions or healthcare-spending slowdowns, insurance companies become cost-conscious and may restrict coverage or demand greater proof of cost-effectiveness. A denial of coverage or a restrictive prior-authorization policy could significantly slow adoption.

NovoCure also faces competition from immunotherapy drugs (checkpoint inhibitors, CAR-T therapies) and traditional chemotherapy. As other oncology companies develop newer chemotherapy regimens or immunotherapies for pancreatic, lung, and mesothelioma cancers, they may challenge Optune’s place in the treatment paradigm. The company’s moat depends on the durability of its clinical data and its ability to generate new evidence showing Optune combined with emerging therapies.

Researching NovoCure as an investment.

The 10-K filing (SEC CIK 0001645113) provides detail on revenue by indication, geographical mix, and reimbursement trends. Pay close attention to the trajectory of patient adoption in each indication and the company’s commentary on reimbursement discussions with major insurance companies.

Clinical trial readouts are the other critical data point. The company’s investor relations website and press releases detail trial results as they arrive. Positive Phase 3 results typically drive stock rallies; delays or negative results drive declines. Investors should monitor the pipeline timeline closely.

Finally, assess the company’s cash position and cash burn. NovoCure has been profitable in recent quarters due to growing pancreatic cancer revenue, but profitability is not guaranteed as the company continues to invest in R&D and commercialisation across new indications. The company’s balance sheet strength is important if a clinical trial fails or if reimbursement is denied in a major market.

NovoCure’s shares are best understood as a play on the emerging acceptance of Tumor Treating Fields as an oncology platform, with substantial upside if pancreatic and lung cancer indications gain market share, and downside risks from clinical setbacks or reimbursement challenges.